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Abstract: Elderly patients with hemophilia have to face new challenges linked to concomitant 
pathologies and concurrent use of different treatments. In order to promote optimal care in the 
elderly hemophilia population, this study is aimed to analyze treatment compliance in relation 
to the presence of comorbidities and the role of potential determinants that can affect compli-
ance (positively or negatively), including health-related quality of life, cognitive decline, and 
sociodemographic parameters (eg, living situation, partnership, presence of caregivers). This 
will be an observational study of elderly patients with hemophilia (aged .60 years). Patients 
will be interviewed during their routine medical visits. The data interview will pertaining to 
several dimension of treatment management. This study will detect more vulnerable patients 
with special care needs and will highlight psychological factors that should be considered for 
future psychosocial interventions.
Keywords: hemophilia, cognitive assessment, cognitive decline, compliance, treatment, 
aging
Background
For patients with hemophilia, life expectancy is now approaching that of the general 
male population, especially in regions and countries that have the resources for regular 
replacement therapy with coagulation-factor concentrates.1 In Italy, for example, nearly 
8% of patients with severe hemophilia A or B are aged 65 years or older.2 The introduc-
tion of virus-inactivated plasma-derived coagulation factors and then of recombinant 
products has radically changed the treatment of patients with hemophilia, improving 
their health-related quality of life (HRQL) and life expectancy.3–6 As a consequence, a 
growing number of patients with hemophilia have reached an older age, and nowadays 
physicians in hemophilia centers “find that they must handle age-related clinical prob-
lems never previously observed in this population”.7–8 The new issues for hemophilia 
care are thus to offer best possible health care for this elderly cohort of patients, who 
frequently present not only with the comorbidities usually linked with hemophilia (such 
as arthropathy, chronic pain, blood-borne infections), but also with general age-related 
conditions such as diabetes, cancer, or cardiovascular disease.8–9
Compliance with a medication regimen is defined as the extent to which patients 
take medications as prescribed by their health providers.3 Compliance is a complex 
behavioral construct highly influenced by the context and the experiences of the 
patients and by the care activities of their health providers. Noncompliance represents 
the extent to which the patient’s behavior does not follow medical instructions or 
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treatment rules.3–4,10 Compliance with treatment is, therefore, 
a crucial determinant of optimal health and quality of life. 
However, it has been reported that adult patients with chronic 
illness take only 50% of their prescribed medication.11–13 The 
situation in elderly patients seems even more problematic. 
Around the 90% of elderly patients make some medication 
errors, and 35% make potentially serious errors.14 Some of 
the explanations as to why elderly patients may experience 
difficulties taking their treatment properly and on time are 
connected to physical limitations (eg, fatigue, arthritis) and 
often to functional limitations, such as memory loss (they 
simply forget to take their medication on time), confusion 
(which occurs especially with multiple drugs and complex 
regimens), emotional problems such as anxiety or depres-
sion, low-quality HRQL, isolation, and scarce social support 
from caregivers.
Scarce compliance is also observed in persons with 
hemophilia and may affect treatment choice: a cross-sectional 
survey conducted in the United States reported that one-third 
of hemophilia physicians do not prescribe prophylaxis due to 
concerns about patient compliance with treatment.15 Based 
on these considerations, the scenario of compliance with 
treatment for elderly patients with hemophilia is emerging 
as deeply worrisome and needs to be evaluated.
Methods
Primary and secondary objectives
The primary objective of this study is to measure the level of 
compliance with treatment prescription (replacement therapy 
and multiple drugs for the treatment of multimorbidity) using 
the following instruments:
•	 The Hemophilia Satisfaction Questionnaire (Hemo-Sat
A
 
for adults)16
•	 The Self-Efficacy for Appropriate Medication Use 
Scale17
•	 REPOSI Appropriateness Drug Prescription Interview.18
The secondary objectives of this study are to assess the 
determinants that affect compliance, including:
•	 The presence of cognitive dysfunction, assessed with the 
Mini–Mental State Examination19
•	 Clinical parameters (eg, bleeding frequency, severity of 
the disease, target joints [that is, three or more bleeds in 
the same joint during the previous 6 months])
•	 Sociodemographic parameters (eg, marital status, living 
situation, education, a series of ad hoc questions pertain-
ing to daily activities, such as “How does the patient fill 
their day”, “How do they go out”, etc)
•	 The presence of caregivers
•	 HRQL, assessed with the Euro-QoL questionnaire 
(EQ-5D-L).20
outcomes
•	 The primary outcome is to estimate the number of vulner-
able elderly patients at risk for poor treatment compliance 
because of cognitive decline, poor HRQL, or sociodemo-
graphic parameters (level of education, living situation, 
partnership, etc).
•	 The secondary outcome is identification of the main 
psychological factors that can be crucial to consider in 
planning future interventions aimed at supporting treat-
ment management in elderly patients with hemophilia.
Study design
This is a prospective noninterventional study (NIS) that 
describes compliance in elderly patients who suffer from 
moderate or severe hemophilia (A or B) and who are receiv-
ing either on-demand treatment or prophylaxis. The study is 
focused on adults (.60 years of age) living in Italy.
This NIS will be conducted and coordinated at the 
Hemophilia Centre of Milan (Italy). However, other Italian 
hemophilia and thrombosis centers will be asked to par-
ticipate in this data collection under the supervision of the 
Hemophilia Centre of Milan. It is anticipated that data from 
approximately 80 patients will be collected.
Patients
The data of patients with a diagnosis of moderate or severe 
hemophilia (A or B), identified by the Hemophilia Centre of 
Milan, will be chosen for collection within this NIS. Patients 
should present the following characteristics:
•	 Male, with hemophilia A or B
•	 Severe or moderate factor deficiency (5% or less)
•	 Age $60 years
•	 Able to read and understand study materials (patient 
information and data protection form, patient-related 
questionnaires)
•	 Having signed the informed consent and data protection 
form
•	 Able to write independently and to complete 
questionnaires.
Withdrawal and replacement of patients
Patients may withdraw from participation in this NIS at any 
time without the need to provide any explanation. Collec-
tion of patient data will be performed as long as source data 
are available and the patient’s permission to document the 
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data has not been withdrawn. No replacement for withdrawn 
patients will be performed.
design and timeframe
In this prospective study, compliance will be assessed over 
a 12-month period in a cohort of adults with hemophilia 
who are receiving routine medical care. Compliance scores 
will be correlated with the results of routine hemophilia 
clinical assessments (eg, therapy for concomitant diseases, 
therapy for bleeding frequency, severity of hemophilia) and 
the results of sociodemographic data related to personal life 
circumstances (eg, perceived HRQL, number and type of 
caregivers).
Variables assessed
Different types of variables will be assessed in the current 
study, including compliance, HRQL, treatment satisfaction, 
and sociodemographic and clinical data. All the questions 
(self-administered) will be presented in a patient booklet for 
each individual patient. The questionnaire administration will 
last around 20 minutes per patient.
Compliance
The Hemo-Sat
A
 Questionnaire represents the first hemophil-
ia-specific treatment satisfaction questionnaire for adults 
developed in Italy. Treatment satisfaction has recently 
become a focus of interest, representing the individual 
rating of the process and outcomes of patients’ treatment 
experience, and is related to adherence and willingness to 
continue treatment. The Hemo-Sat
A
 consists of 34 items 
pertaining to six dimensions (“ease and convenience”, 
“efficacy”, “burden”, “specialist”, “center”, and “general 
satisfaction”).18
The Self-Efficacy for Appropriate Medication Use Scale 
was developed on the basis of Bandura’s social cognitive 
theory. This instrument was developed for patients with a 
chronic disease.17 Patients are asked about how confident they 
were that they did take their medications accurately (uncon-
fident =1, fairly confident =2, and extremely confident =3). 
The lowest possible score of the 13-item questionnaire is 
13, and the highest possible score is 39; the high score indi-
cates that the participant is highly confident about taking 
medication.
The REPOSI Appropriateness Drug Prescription Inter-
view is a short new instrument that assesses the appropriate-
ness of drug prescriptions in relation to polypharmacy.18 It 
has recently been proposed and implemented in the context 
of the REPOSI (REgistro POliterapie, SIMI) Study, a 
noninterventional, multicenter registry designed to collect 
a set of clinical and laboratory data on elderly patients con-
secutively hospitalized. The interview is composed of nine 
questions that aim to review the number of drugs prescribed 
and to check their appropriateness.
Cognitive profile
The Mini-Mental State examination, or Folstein test, is 
a brief 30-point questionnaire that is used to screen for 
cognitive impairment. It is commonly used in medicine to 
screen for dementia. It is also used to estimate the sever-
ity of cognitive impairment and to follow the course of 
cognitive changes in an individual over time, thus making 
it an effective way to document an individual’s response 
to treatment.19
Health-related quality of life
The EQ-5D-3L is a standardized instrument for use as a 
measure of health outcomes. Applicable to a wide range of 
health conditions and treatments, the EQ-5D health question-
naire provides a simple descriptive profile and a single index 
value for health status. The EQ-5D-3L consists of two pages, 
the EQ-5D descriptive system and a visual analog scale. The 
EQ-5D-3L descriptive system comprises the following five 
dimensions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. Each dimension has three levels: 
no problems, some problems, extreme problems.20
Table 1 shows the clinical and sociodemographic data 
that will be obtained by the physician and inserted in the 
Medical Documentation Form.
Table 1 Clinical and sociodemographic data
Clinical data Sociodemographic data
Inclusion/exclusion criteria Marital status (past, current)
demographics Partnership
Bleeding history living situation (eg, household size, 
geographical location)
target joints Education (school level will be 
asked according to the International 
Standard Classification of Education*)
Inhibitor history Professional situation  
(eg, employment status)
Viral infections daily life activities functioning
Concomitant diseases
Surgery
replacement therapy regimen
Concomitant drugs other  
than replacement therapy
Medical visits
Note: *UNESCO developed the International Standard Classification of Education 
(ISCEd) to facilitate comparisons of education statistics and indicators across 
countries on the basis of uniform and internationally agreed definitions.
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Statistical analysis
Sample size determination
This is an NIS, and the statistical approach is exploratory 
in nature. A sample size of 80 patients aged .60 years has 
been estimated, for the following reasons:
1. The mean ± standard deviation of the Hemo-Sat
A
 in 29 
adult patients with hemophilia (the only available mea-
sure on compliance in a cohort of hemophiliac patients) 
was reported as 21.4±25.7. Scores range from 0 to 100; 
a lower score indicates higher satisfaction.21 Assuming 
that this variability is also representative of other groups, 
and further, that a relevant effect to be detected between 
ages (younger and older) amounts to 23 points on this 
scale, leading to an effect size of 0.75, then 70–90 patients 
should be enrolled per region (approximately 80 patients 
overall) with a precision of 95% (ie, 95% confidence 
interval [CI]). The power to detect significant differences 
between determinants (eg, cognitive decline) with a fairly 
balanced distribution in this case reaches 81%–96%.
2. This seems to be a reasonable number to collect, taking 
into account that hemophilia is a rare disease and the 
prevalence of elderly hemophiliacs, even if increasing, 
is still limited in the Italian centers.
3. In this area, as cited by the review of Schrijvers et al22 
on compliance in elderly hemophiliacs, the mean sample 
size of the five studies cited was 80 participants (range, 
38–147 participants).
4. Statistically, this is a correlational study aimed to identify cor-
relations and/or associations between aging and compliance. 
In a correlational study, a limited sample size is commonly 
accepted.23
Statistical data
The study objective is addressed in an exploratory manner to 
identify compliance in elderly patients with hemophilia and 
the determinants that strongly impact compliance (HRQL, 
cognitive assessment, the presence of caregivers, clinical 
parameters, sociodemographic parameters).
Compliance and determinants (HRQL, cognitive assess-
ment, the presence of caregivers, clinical parameters, socio-
demographic parameters) will be analyzed descriptively for 
each measure point by means of frequency, median, mean, 
standard deviation, range, and 95% CIs. Compliance dif-
ferences between different patient groups (eg, prophylaxis 
versus on-demand, polytherapy versus non-polytherapy, 
family status, personal life circumstances, etc.) will be 
assessed using inference statistical analysis (Mann–Whitney 
U-test or Kruskall–Wallis test for categorical determinants; 
P-values ,0.05 will be regarded as nominally significant in 
double-sided tests). For ordinal or continuous determinants, 
correlations and regressions will be calculated (Spearman 
or Pearson correlation) to identify a potential relationship 
between these factors (eg, number of bleeding events, sports 
activity, and educational level) and study endpoints (compli-
ance). Finally, a cluster analysis (hierarchical, K-mean) will 
be performed. Cluster analysis is an exploratory data analysis 
tool that aims at sorting different objects (eg, traits, charac-
teristics) into groups in a way that the degree of association 
between two objects is maximal if they belong to the same 
group and minimal otherwise. Given the above study objec-
tive, cluster analysis will permit identification of different 
compliance profiles, discovering the most peculiar traits and 
patients’ characteristics in each cluster.
All statistical analysis will be performed using SAS/STAT 
software version 9.1 (SAS Institute Inc., Cary, NC, USA). 
The Proc GLIMMIX was used to fit mixed methods.
Project activities
data handling procedures
A documentation form will be completed for each patient. 
The documentation forms will be reviewed for accuracy and 
completeness by the Principal Investigator (PI). Computer-
aided data validations using preset procedures will be per-
formed on an ongoing basis. Coding of medical terms and 
medication will be done using the current versions of coding 
dictionaries (ie, Medical Dictionary for Regulatory Activi-
ties, World Health Organization-Drug Dictionary enhanced). 
Questionnaire data will be transformed into SPSS for further 
and detailed analysis, which will be performed by the PI, who 
is expert in HRQL analysis.
Ethical conduct and good clinical practice
This study will be conducted in accordance with national 
laws. Ethics committees and national agencies will be 
informed or asked for approval. Regulations on data protec-
tion will be adhered to (eg, Directive 95/46/EC). This study 
is carried out completely independent of any medicinal 
treatment recommendations. Patients will be assessed and 
treated according to the individual decision of the attending 
physician. The study will not provide any recommendations 
with regard to diagnostic procedures or dosages, time of 
intake, or the strength of any medication.
data protection form
It is the responsibility of the PI or a designated person (if 
acceptable according to local regulations), to obtain written 
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consent to data collection from each patient participating in 
this study after adequate explanation of the objectives of data 
collection. It will also be explained to the patients that they 
will be fully free to allow or refuse the use of their data for 
the purposes of this study.
Appropriate forms for obtaining written consent to data 
collection will be provided to all patients.
Timeline
duration
The study period will be divided into two phases: a recruit-
ment phase of up to 3 months, followed by a data collection 
phase of 6 months. The end of the data collection is defined 
as the last appointment of the last patient participating in the 
study (Table 2).
Conclusion
The project aims to evaluate patient compliance with treat-
ment, which should help in the management of elderly 
patients with hemophilia. In Italy, treatment compliance in 
elderly hemophiliacs represents an innovative topic that is 
still understudied. No data are available and no information 
about risks and polytherapy are currently described in such a 
cohort. This study has the potential to evaluate compliance for 
the first time in Italian hemophilia centers and to be included 
in future studies conducted in the hemophilia community.
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